title: Biochemical and pathological evidences on the benefit of a new biodegradable nanoparticles of probiotic extract in murine colitis.
abstract: Efficacy of probiotics in the management of human inflammatory bowel disease (IBD) has been approved in the recent years. In the present work, the efficacy of a new biodegradable nanoparticles (NPs) of encapsulated and lyophilized probiotic extract (LPE) was examined in murine colitis. Colitis was induced by rectal instillation of trinitrobenzen sulfonic acid to male Wistar rats. The safety and effective dose of LPE was determined in a pilot study. To ease delivery into colon, LPE was encapsulated in chitosan-coated-poly (lactide co glycolide acid) NPs. After induction of colitis, animals in different groups received test compound in three doses by gavage for 10 days. Groups of sham, control (saline), and standard (dexamethasone) were also assigned. Colonic pathological examination, tumor necrosis factor alpha, interlukin (IL)-1β, myeloperoxidase (MPO), and lipid peroxidation (LPO) were performed. LPE at all doses (273, 545, and 1100 mg/kg) had positive effects in reduction of pro-inflammatory cytokines, LPO, and MPO in a dose-dependent manner. The formulated compound containing medium dose of LPE was more efficient in mitigating the experimental colitis in comparison with that of high-dose LPE. It is concluded that LPE and its nanoparticle-encapsulated form are very much effective in control of colitis. Regarding safety of this compound, further studies can be conducted in patients with IBD.
authors.affiliation: Department of Pharmaceutics, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Afrooz
authors.initials: A
authors.lastname: Saadatzadeh
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Atyabi
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Fazeli
authors.forename: Rassoul
authors.initials: R
authors.lastname: Dinarvand
authors.forename: Hossein
authors.initials: H
authors.lastname: Jamalifar
authors.forename: Amir Hossein
authors.initials: AH
authors.lastname: Abdolghaffari
authors.forename: Parvin
authors.initials: P
authors.lastname: Mahdaviani
authors.forename: Mirgholamreza
authors.initials: M
authors.lastname: Mahbod
authors.forename: Maryam
authors.initials: M
authors.lastname: Baeeri
authors.forename: Amir
authors.initials: A
authors.lastname: Baghaei
authors.forename: Azadeh
authors.initials: A
authors.lastname: Mohammadirad
authors.forename: Mohammad
authors.initials: M
authors.lastname: Abdollahi
mesh_terms: D000818:Animals; D048271:Chitosan / Q000737:chemistry; D003092:Colitis / Q000473:pathology / Q000628:therapy*; D016207:Cytokines / Q000378:metabolism; D003907:Dexamethasone / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005612:Freeze Drying; D018836:Inflammation Mediators / Q000378:metabolism; D019344:Lactic Acid / Q000737:chemistry; D015227:Lipid Peroxidation; D008297:Male; D053758:Nanoparticles; D010865:Pilot Projects; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D014302:Trinitrobenzenesulfonic Acid
chemical_list: D016207:Cytokines; D018836:Inflammation Mediators; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D003907:Dexamethasone; D014302:Trinitrobenzenesulfonic Acid; D048271:Chitosan